According to the share adoption announcement, the company is planning to acquire no less than 20% of Zhejiang Peptide Biotech Co., Ltd.'s shares through cash payment. On September 24, 2026, it signed a “Letter of Intent to Acquire” with 7 shareholders including Xing Haiying and Peptide Biotech. This transaction is not expected to constitute a major asset restructuring and does not involve issuing shares. The specific transaction target, acquisition ratio, price, etc. will need to be determined through negotiations based on due diligence, audit and evaluation results, and the formal acquisition agreement shall prevail. The exclusion period is until March 31, 2027. If the counterparty violates the exclusivity agreement, a penalty of 5 million yuan will be charged. The deal is still in the planning stage, and there is uncertainty about whether it will be finalized.

According to the share adoption announcement, the company is planning to acquire no less than 20% of Zhejiang Peptide Biotech Co., Ltd.'s shares through cash payment. On September 24, 2026, it signed a “Letter of Intent to Acquire” with 7 shareholders including Xing Haiying and Peptide Biotech. This transaction is not expected to constitute a major asset restructuring and does not involve issuing shares. The specific transaction target, acquisition ratio, price, etc. will need to be determined through negotiations based on due diligence, audit and evaluation results, and the formal acquisition agreement shall prevail. The exclusion period is until March 31, 2027. If the counterparty violates the exclusivity agreement, a penalty of 5 million yuan will be charged. The deal is still in the planning stage, and there is uncertainty about whether it will be finalized.